{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-24-000025","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.243594+00:00","generated_at":"2026-05-30T04:59:16.958736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance","bullets":["GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.","Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).","Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.","Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.","Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-24-000025","json":"https://secwatch.observer/filing/0000882095-24-000025.json","markdown":"https://secwatch.observer/filing/0000882095-24-000025.md","text":"https://secwatch.observer/filing/0000882095-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/0000882095-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/gild-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:59:16.958736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}